Neurotrophic Factor GDF5 - an alternative to GDNF?
Neurotrophic factors are small protein that are naturally produced in the brain to help nurture and protect nerve cells (neurons). Cure Parkinson's is a strong supporter of research exploring neurotrophic factors as a future therapeutic strategy for Parkinson's.
Learn more
New potential drugs for repurposing in Parkinson’s
The development of new drugs is a long and expensive process, taking many years of funding to bring new therapeutics to treat diseases. Drug repurposing offers a means of rapidly testing already available medicines in diseases that they were not originally approved for.
The 2021 International Linked Clinical Trials Meeting
The International Linked Clinical Trials (iLCT) programme is the flagship drug repurposing initiative of Cure Parkinson’s and Van Andel Institute (VAI) focussed on identifying and clinically testing already available drugs that show potential to slow, stop or reverse the progression of Parkinson’s. Every year the iLCT…
Results from the Inosine SURE-PD clinical trial
The results of a large clinical trial, of 300 individuals, of the dietary supplement ‘inosine’ have shown that the treatment had no effect on slowing the progression of Parkinson’s. Inosine elevates levels of urate in the body. Urate is a naturally produced antioxidant that circulates…
The Anle138b Trial
This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic. This trial, it is hoped, will slow-down…
The clinical trials pipeline for Parkinson’s: 2020/21
Despite the difficulties throughout 2020, a significant amount of clinical trial activity for Parkinson’s was conducted and a new report – involving the research team at Cure Parkinson’s – highlights the landscape of therapeutics being developed for Parkinson’s.